ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

9:00AM-11:00AM: Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

9:00AM-11:00AM: Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Innate Immunity Poster

9:00AM-11:00AM: Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Osteoporosis & Metabolic Bone Disease Poster

9:00AM-11:00AM: Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity

9:00AM-11:00AM: RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

9:00AM-11:00AM: SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:00AM-10:50AM: Imaging of Rheumatic Diseases (0444–0448)

10:00AM-10:50AM: Infection-related Rheumatic Disease (0454–0458)

10:00AM-10:50AM: Miscellaneous Rheumatic & Inflammatory Diseases I: Mechanisms of Disease (0459–0463)

10:00AM-10:50AM: Professional Education (0474–0478)

11:30AM-1:00PM: Plenary Session I (0429–0433)

3:00PM-3:50PM: Immunological Complications of Therapy (0449–0453)

3:00PM-3:50PM: RA – Diagnosis, Manifestations, & Outcomes I: Pre-Onset & Early RA (0479–0483)

3:00PM-3:50PM: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Psoriatic Arthritis (0504–0508)

3:00PM-3:50PM: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA, Behçet’s, & Relapsing Polychondritis (0509–0513)

4:00PM-4:50PM: Clinical Practice I (0434–0438)

4:00PM-4:50PM: Healthcare Disparities in Rheumatology (0439–0443)

4:00PM-4:50PM: RA – Diagnosis, Manifestations, & Outcomes II: The Heart of the Matter (0484–0488)

4:00PM-4:50PM: Vasculitis – Non-ANCA-Associated & Related Disorders II: GCA Clinical & Epidemiology (0514–0518)

5:00PM-5:50PM: Patient Outcomes, Preferences, & Attitudes I: COVID-19 (0464–0468)

5:00PM-5:50PM: Pediatric Rheumatology – Basic Science (0469–0473)

5:00PM-5:50PM: RA – Diagnosis, Manifestations, & Outcomes III: Major Comorbidities in RA (0489–0493)

5:00PM-5:50PM: SLE – Etiology & Pathogenesis (0494–0498)

5:00PM-5:50PM: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Psoriatic Arthritis (0499–0503)

Saturday, November 7, 2020

9:00AM-11:00AM: Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

9:00AM-11:00AM: Health Services Research Poster

9:00AM-11:00AM: Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Metabolic & Crystal Arthropathies Poster

9:00AM-11:00AM: Orthopedics, Low Back Pain, & Rehabilitation Poster

9:00AM-11:00AM: Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Pediatric Rheumatology – Clinical Poster II: JIA

9:00AM-11:00AM: RA – Animal Models Poster

9:00AM-11:00AM: RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

9:00AM-11:00AM: RA – Etiology & Pathogenesis Poster

9:00AM-11:00AM: RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

9:00AM-11:00AM: SLE – Animal Models Poster

9:00AM-11:00AM: SLE – Treatment Poster I

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

9:00AM-11:00AM: Systemic Sclerosis & Related Disorders – Clinical Poster II

10:00AM-10:50AM: Fibromyalgia & Other Clinical Pain Syndromes (0940–0944)

10:00AM-10:50AM: Innate Immunity (0945–0949)

10:00AM-10:50AM: Muscle Biology, Myositis & Myopathies (0955–0959)

10:00AM-10:50AM: Orthopedics, Low Back Pain, & Rehabilitation (0960–0964)

11:30AM-1:00PM: Plenary Session II (0934–0939)

3:00PM-3:50PM: RA – Etiology & Pathogenesis (0970–0974)

3:00PM-3:50PM: SLE – Animal Models (0975–0979)

3:00PM-3:50PM: SLE – Treatment (0985–0989)

5:00PM-5:50PM: Metabolic & Crystal Arthropathies (0950–0954)

5:00PM-5:50PM: RA – Animal Models (0965–0969)

5:00PM-5:50PM: SLE – Diagnosis, Manifestations, & Outcomes I: Morbidity (0980–0984)

Sunday, November 8, 2020

9:00AM-11:00AM: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

9:00AM-11:00AM: Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Patient Perspectives Poster

9:00AM-11:00AM: Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma

9:00AM-11:00AM: RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

9:00AM-11:00AM: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

9:00AM-11:00AM: Sjögren’s Syndrome Poster

9:00AM-11:00AM: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Vasculitis – ANCA-Associated Poster

10:00AM-10:50AM: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1452–1456)

10:00AM-10:50AM: Clinical Practice II (1457–1461)

10:00AM-10:50AM: Miscellaneous Rheumatic & Inflammatory Diseases II: Evaluating Drug Therapies for COVID-19 (1477–1481)

11:30AM-1:00PM: Plenary Session III (1441–1446)

12:00PM-1:00PM: Patient Perspectives (PP09–PP12)

3:00PM-3:50PM: Epidemiology & Public Health I: RA (1462–1466)

3:00PM-3:50PM: Reproductive Issues in Rheumatic Disorders (1497–1501)

3:00PM-3:50PM: SLE – Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (1507–1511)

3:00PM-3:50PM: Systemic Sclerosis & Related Disorders – Basic Science (1522–1526)

4:00PM-4:50PM: Antiphospholipid Syndrome (1447–1451)

4:00PM-4:50PM: Epidemiology & Public Health II: Risk Factors & Outcomes (1467–1471)

4:00PM-4:50PM: Osteoarthritis I: Clinical Trials (1482–1486)

4:00PM-4:50PM: Pediatric Rheumatology – Clinical I: Treatment of JIA (1492–1496)

4:00PM-4:50PM: SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516)

5:00PM-5:50PM: Epidemiology & Public Health III: Risk Factors & Outcomes (1472–1476)

5:00PM-5:50PM: Osteoarthritis II: Clinical Aspects (1487–1491)

5:00PM-5:50PM: Sjögren’s Syndrome (1502–1506)

5:00PM-5:50PM: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1517–1521)

Monday, November 9, 2020

9:00AM-11:00AM: Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Imaging of Rheumatic Diseases Poster

9:00AM-11:00AM: Immunological Complications of Therapy Poster

9:00AM-11:00AM: Late-Breaking Posters

9:00AM-11:00AM: Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies

9:00AM-11:00AM: Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

9:00AM-11:00AM: Professional Education Poster

9:00AM-11:00AM: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

9:00AM-11:00AM: Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: SLE – Treatment Poster II

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

9:00AM-11:00AM: Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:00AM-10:50AM: Health Services Research (1958–1962)

10:00AM-10:50AM: Pediatric Rheumatology – Clinical II: Outcomes & Care Delivery (1983–1987)

10:00AM-10:50AM: RA – Treatments I: Maximizing Health in RA (1993–1997)

10:00AM-10:50AM: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2043–2047)

11:00AM-11:50AM: Patient Outcomes, Preferences, & Attitudes II: Engagement, Perceptions, & Quality of Life (1978–1982)

11:00AM-11:50AM: Pediatric Rheumatology – Clinical III: Systemic Autoimmune Disease (1988–1992)

11:00AM-11:50AM: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Emerging Therapies (2023–2027)

11:00AM-11:50AM: Vasculitis – ANCA-Associated (2048–2052)

11:30AM-1:00PM: Late-Breaking Abstracts (L06–L11)

12:00PM-12:50PM: Genetics, Genomics & Proteomics (1953–1957)

12:00PM-12:50PM: Measures & Measurement of Healthcare Quality (1963–1967)

12:00PM-12:50PM: Osteoarthritis & Joint Biology – Basic Science (1968–1972)

12:00PM-12:50PM: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II (2013–2017)

3:00PM-3:50PM: Cytokines & Cell Trafficking (1948–1952)

3:00PM-3:50PM: Osteoporosis & Metabolic Bone Disease (1973–1977)

3:00PM-3:50PM: RA – Treatments II: Potential Harms & Adverse Events (1998–2002)

3:00PM-3:50PM: Systemic Sclerosis & Related Disorders – Clinical I: Stratification Strategies for Clinical Trials (2033–2037)

4:00PM-4:50PM: RA – Treatments III: Predictors of Treatment Response (2003–2007)

4:00PM-4:50PM: Spondyloarthritis Including Psoriatic Arthritis – Treatment III: Axial Spondyloarthritis (2028–2032)

4:00PM-4:50PM: Systemic Sclerosis & Related Disorders – Clinical II: Lessons Learned from Clinical Trials & Cohorts (2038–2042)

5:00PM-5:50PM: RA – Treatments IV: New Therapies & Strategies (2008–2012)

5:00PM-5:50PM: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes III: Imaging in SpA (2018–2022)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].